Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Applied Biologics initiates multi-center real-world outcomes study of XWRAP® across chronic wound types.
-
Applied Biologics announces submission of XWRAP® translational research abstract to SAWC Fall 2026.
-
Applied Biologics announces manufacture of its first research construct for the preclinical DMOAD Gene Therapy Program.
-
Applied Biologics introduces ECM Preservation Technology™ (EPT™), the proprietary manufacturing platform behind XWRAP®.
-
Applied Biologics' VA FSS contract shifts to Evergreen structure, enabling potential XWRAP® access for up to 20 years.
-
Applied Biologics expands strategic focus to surgical applications of XWRAP® across multiple specialties.
-
Applied Biologics expands its national commercial organization to support XWRAP® growth and future pipeline commercialization.
-
Applied Biologics completes translational study showing XWRAP® exhibits favorable wound-healing biology vs. conventional placental tissue processing.
-
Applied Biologics submits CAMPX Trial abstract to SAWC Fall 2026, showing XWRAP improved DFU closure rates to 30.9% vs. 17.5% for standard of care alone.
-
Applied Biologics completes enrollment in the CAMPX RCT evaluating XWRAP® for chronic diabetic foot ulcers across 23 SerenaGroup sites.